Policy, regulations, AI and CRDMO take centre stage at the flagship event of the Department of Pharmaceuticals
At the centre of this shift is Eli Lilly and Company, whose latest investments in China and Japan are helping redefine the next phase of GLP-1 supply strategy
This event will bring together global stakeholders to explore India’s growing capabilities in pharma and biopharma innovation, research, and manufacturing
The two-day conference and exhibition features discussions on policy frameworks, AI-led drug discovery, next-generation technologies, and global competitiveness
The partnership aims to fuse antibody-drug conjugation (ADC) technology with targeted protein degradation
The device aims to bring precision neuroscience into clinical trials, accelerating drug development
In just the last few days, companies including Lupin, Biocon, Alembic Pharmaceuticals and Aurobindo Pharma have announced approvals for 5 mg and 10 mg tablets, all bioequivalent to Farxiga
Interchangeable biosimilars to Prolia and Xgeva target osteoporosis and cancer-related bone complications in a $5 billion U.S. market
Immediate U.S. launch planned for Farxiga®-equivalent diabetes drug; opportunity pegged at $10.2 billion in annual market size
Immediate opportunity in the $10.2 billion U.S. market as the diabetes therapy will be manufactured at Zydus’ SEZ Ahmedabad facility
Subscribe To Our Newsletter & Stay Updated
